These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22020767)

  • 1. [The serine/threonine kinases that control cell cycle progression as therapeutic targets].
    Diallo A; Prigent C
    Bull Cancer; 2011 Nov; 98(11):1335-45. PubMed ID: 22020767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    Schöffski P
    Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
    Warner SL; Gray PJ; Von Hoff DD
    Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15.
    Iavarone A; Massagué J
    Nature; 1997 May; 387(6631):417-22. PubMed ID: 9163429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic opportunities to control tumor cell cycles.
    Malumbres M
    Clin Transl Oncol; 2006 Jun; 8(6):399-408. PubMed ID: 16790392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo and Aurora kinases: lessons derived from chemical biology.
    Taylor S; Peters JM
    Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
    Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
    Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.
    Pitts TM; Davis SL; Eckhardt SG; Bradshaw-Pierce EL
    Pharmacol Ther; 2014 May; 142(2):258-69. PubMed ID: 24362082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shared and separate functions of polo-like kinases and aurora kinases in cancer.
    Lens SM; Voest EE; Medema RH
    Nat Rev Cancer; 2010 Dec; 10(12):825-41. PubMed ID: 21102634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
    Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
    Chopra P; Sethi G; Dastidar SG; Ray A
    Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I.
    Iwanaga R; Ohtani K; Hayashi T; Nakamura M
    Oncogene; 2001 Apr; 20(17):2055-67. PubMed ID: 11360190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases.
    Greider C; Chattopadhyay A; Parkhurst C; Yang E
    Oncogene; 2002 Nov; 21(51):7765-75. PubMed ID: 12420213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
    Liang YC; Lin-Shiau SY; Chen CF; Lin JK
    J Cell Biochem; 1999 Oct; 75(1):1-12. PubMed ID: 10462699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-beta 1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells.
    Kamesaki H; Nishizawa K; Michaud GY; Cossman J; Kiyono T
    J Immunol; 1998 Jan; 160(2):770-7. PubMed ID: 9551912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.
    Zhang Z; Xing X; Guan P; Song S; You G; Xia C; Liu T
    Eur J Med Chem; 2021 May; 217():113314. PubMed ID: 33765606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
    Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLK1 inhibitors: setting the mitotic death trap.
    Plyte S; Musacchio A
    Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.
    Warner SL; Stephens BJ; Von Hoff DD
    Curr Oncol Rep; 2008 Mar; 10(2):122-9. PubMed ID: 18377825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel anti-cancer compounds targeting the cell cycle].
    Hirai H; Shimomura T; Komatani H; Kotani H
    Nihon Yakurigaku Zasshi; 2009 Jan; 133(1):27-31. PubMed ID: 19145048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.